Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia

American Journal of the Medical Sciences

Volumn 347, Issue 3, 2014, Pages 254-255

  Murphy, Martina ^a   Close, Julia ^a   Lottenberg, Richard ^a   Rajasekhar, Anita ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEMOGLOBIN A2; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; IMATINIB; MORPHINE; ORAL CONTRACEPTIVE AGENT; OXYCODONE;

ADULT; ALPHA THALASSEMIA; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME 9; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CYTOGENETICS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; HOMOZYGOSITY; HUMAN; HYPOPIGMENTATION; KARYOTYPE 46,XX; LETTER; LEUKEMIA REMISSION; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTOSIS; LYMPHOCYTE; MEDICATION COMPLIANCE; MENSTRUATION; NAUSEA; NEUTROPHIL; NIGHT SWEAT; PAIN; PATIENT COMPLIANCE; REAL TIME POLYMERASE CHAIN REACTION; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SICKLE CELL PAIN; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ADULT; ANEMIA, SICKLE CELL; ANTINEOPLASTIC AGENTS; BENZAMIDES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PAIN; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84896728044     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000228     Document Type: Article

References (7)

1. Stankovic KS, Brigitte T, Garandeau E, et al. Chronic myeloid leukaemia and sickle cell disease: Could imatinib prevent vaso-occlusive crisis? Br J Haematol 2011;155:271-2.
2. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal. Blood 2012;120:3647-56.
3. Hartmann JT, Haap M, Kopp HG, et al. Tyrosine kinase inhibitors-A review on pharmacology, metabolism, and side effects. Curr Drug Metab 2009;10:470-81.
4. Okpala I. The intriguing contribution of white blood cells to sickle cell disease-A red cell disorder. Blood Rev 2004;18:65-73.
5. Frenette PS. Sickle cell vasoocclusion: Heterotypic, multicellular aggregations driven by leukocyte adhesion. Microcirculation 2004;11: 167-77.
6. Vincent L, Vang D, Nguyen J, et al. Mast cell activation contributes to sickle cell pathobiology and pain. Blood 2013;122:1853-62.
7. Wang Y, Barker K, Shi S, et al. Blockade of PDGFR-b activation inhibits morphine analgesic tolerance. Nat Med 2012;18:385-7.